Dr Osborne is one of the co-founders of Arcutis, and is a prominent expert in pharmaceutical product development, specializing in the topical, transdermal, transmucosal, and subcutaneous delivery of active pharmaceutical ingredients through creams, gels, and ointments. Prior to Arcutis, he was chief scientific officer at Tolmar, and before that, vice president of product development at Dow Pharmaceutical Sciences, and earlier, ViroTex/Atrix. He started his career as a formulation group leader at The Upjohn Company and then a Merck subsidiary.
Dr Osborne has 29 issued US patents, is a named inventor on 4 FDA-approved topical products, and led the development of Eligard®, Clobex® Spray, MetroGel® 1%, and 15 generic topical products. He has 58 publications, primarily in the areas of surfactants, formulations, and skin delivery, and edited 2 books on topical drug development. He was the 1992 chairman of the ACS Division of Colloid and Surface Chemistry, and founding North American editor of the journal Colloids and Surfaces: Biointerfaces. He received his BSc in chemistry from Missouri State University, and a PhD in physical chemistry from Missouri Science and Technology.